Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
CRG UZ Brussel
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03088046CT.gov Circulating Androgen Levels Are Not Affected by the Administration of Vaginal Micronized Progesterone for Withdrawal Bleeding in Patients With Polycystic Ovarian Syndrome | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Anovulation
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Progesterone (this asset) | CRG UZ Brussel | Approved | BB · 64 |
| Clomiphene Citrate | Xiyuan Hospital of China Academy of Chinese Medical Sciences | P4 | BBB |
| Letrozole | GABRIEL MONTEIRO PINHEIRO | P4 | BBB |
| Metformin | Ain Shams Maternity Hospital | P4 | BBB |
| Recombinant Human Follicle Stimulating Hormone | University of California, San Diego | P4 | BB |
| Human Chorionic Gonadotropin | Assiut University | P3 | BB |
| Folate | University Magna Graecia | P4 | BB |
| Gonadorelin | RenJi Hospital | P4 | BB |
| Follitropin Alfa | Merck KGaA, Darmstadt, Germany | P3 | BB |
+7 more in the Anovulation cohort
Other indications for Progesterone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Polycystic Ovary Syndrome | — | P4 | BB · 71 |
| Traumatic Brain Injury | — | P4 | BB · 67 |
| Infertility Disorder | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Progesterone in Anovulation. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/progesterone-anovulation
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →